Trial Profile

Clinical study of of MGX-001 as curative treatment for both adults and children with hemophilia A.

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 22 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MGX 001 Metagenomi (Primary)
Indications Haemophilia A
Focus Adverse reactions; First in man; Therapeutic Use

Most Recent Events

22 Aug 2024 New trial record
14 Aug 2024 According to Metagenomi, Inc. media release, the company plans to initiate IND enabling activities in 2024 and to file an IND to US FDA for Haemophilia A in 2026 .

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com